138 related articles for article (PubMed ID: 30503050)
1. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
Torres D; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Wang C; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):223-227. PubMed ID: 30503050
[TBL] [Abstract][Full Text] [Related]
2. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Torres D; Wang C; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Konecny GE; Goode EL; Cliby WA
Gynecol Oncol; 2018 Aug; 150(2):227-232. PubMed ID: 29925470
[TBL] [Abstract][Full Text] [Related]
3. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
Kumar A; Janco JM; Mariani A; Bakkum-Gamez JN; Langstraat CL; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Jan; 140(1):15-21. PubMed ID: 26541980
[TBL] [Abstract][Full Text] [Related]
4. Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Kumar A; Wang C; Sheedy SP; McCauley BM; Winham SJ; Ramus SJ; Anglesio MS; Kim B; Torres D; Keeney GL; Cliby WA; Goode EL
Gynecol Oncol; 2022 Sep; 166(3):508-514. PubMed ID: 35931468
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
7. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
[TBL] [Abstract][Full Text] [Related]
8. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
Torres D; Kumar A; Wallace SK; Bakkum-Gamez JN; Konecny GE; Weaver AL; McGree ME; Goode EL; Cliby WA; Wang C
Gynecol Oncol; 2017 Dec; 147(3):503-508. PubMed ID: 28964622
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
11. Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
Heus C; Smorenburg A; Stoker J; Rutten MJ; Amant FCH; van Lonkhuijzen LRCW
Gynecol Oncol; 2021 Jan; 160(1):187-192. PubMed ID: 33393479
[TBL] [Abstract][Full Text] [Related]
12. Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
Di Donato V; Di Pinto A; Giannini A; Caruso G; D'Oria O; Tomao F; Fischetti M; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2021 Apr; 161(1):4-10. PubMed ID: 33223220
[TBL] [Abstract][Full Text] [Related]
13. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
Kanbergs AN; Manning-Geist BL; Pelletier A; Sullivan MW; Del Carmen MG; Horowitz NS; Growdon WB; Clark RM; Muto MG; Worley MJ
Gynecol Oncol; 2020 Dec; 159(3):687-691. PubMed ID: 32951891
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal cancer index predicts severe complications after ovarian cancer surgery.
Lomnytska M; Karlsson E; Jonsdottir B; Lejon AM; Stålberg K; Poromaa IS; Silins I; Graf W
Eur J Surg Oncol; 2021 Nov; 47(11):2915-2924. PubMed ID: 34053777
[TBL] [Abstract][Full Text] [Related]
16. Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
Uccella S; Mele MC; Quagliozzi L; Rinninella E; Nero C; Cappuccio S; Cintoni M; Gasbarrini A; Scambia G; Fagotti A
Gynecol Oncol; 2018 May; 149(2):263-269. PubMed ID: 29550182
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction.
Mohammad A; Ainio C; Narasimhulu DM; McGree M; Weaver AL; Kumar A; Garbi A; Mariani A; Aletti G; Multinu F; Langstraat C; Cliby W
Int J Gynecol Cancer; 2023 May; 33(5):727-733. PubMed ID: 36750269
[TBL] [Abstract][Full Text] [Related]
19. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
